Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in NTLA.
← Back to Free Index

NTLA

Analysis as of: 2026-11-07
Intellia Therapeutics, Inc.
Clinical-stage biotechnology company developing in vivo CRISPR gene-editing therapies for hereditary angioedema, transthyretin amyloidosis and other severe diseases.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

First approval could reprice a fragile platform
The upside case is a transition from collaboration revenue to owned rare-disease product economics, with a second franchise behind it. The risk is that approval arrives before payer, site and follow-on clinical proof catch up.

Analysis

Thesis
If lonvo-z wins approval and launch execution is competent, Intellia can shift from low-quality collaboration revenue to owned rare-disease product revenue, while nex-z and selective platform deals add a second value layer; that supports a realistic 3-4x enterprise value path by 2031 without needing platform euphoria.
Last Economy Alignment
Moderately positive: AI helps discovery and execution around an IP-heavy, regulated therapy model, but biology, manufacturing, payers and regulators still set the pace.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.5x (from 5 most recent analyses)
Reasoning
The rerating case is a business-model upgrade, not just a science win. First approval would move revenue mix from collaboration payments to owned therapy economics, treatment-center and payer workflows can create stickier distribution than a normal orphan launch, and nex-z plus selective partnering can keep the story from collapsing into a single-asset view. I do not underwrite a 10x outcome because regulation, launch friction and financing risk still cap the upside.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
This is a path-dependent biotech transition story. Lonvo-z approval, payer and treatment-center conversion, and later ATTR proof each unlock the next layer of value. Intellia has enough cash to reach the first gate, but it still faces concentrated regulatory risk, unproven launch unit economics for a one-time therapy, and the chance that approval validates the science more than durable market share.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.31
They own regulated gene-editing know-how and may control the first one-time CRISPR treatment in hereditary angioedema, so approval could turn hard science into trusted revenue. But AI cannot shortcut the real chokepoints here: regulators, manufacturing, payer access and treatment-center execution.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$22.83
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case